Acurx enrolls first patient in PATHFINDER trial for C. difficile

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to Acurx enrolls first patient in PATHFINDER trial for C. difficile

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

September 29, 2026 8:01 AM EDT

PATHFINDER is a ground-breaking Phase 2 clinical trial with ibezapolstat (IBZ) in patients with multiply-recurrent CDI (C. difficile Infection) (rCDI) that, together with results from the planned ASPIRE Phase 3 trial in the broader patient population for the treatment of acute CDI, has potential to shift the paradigm of treatment and prevention of rCDI from two agents to one PATHFINDER by itself  in patients with multiply-recurrent CDI will inform elements of a planned active-controlled, Phase 3 registration trial in  rCDI. Upon subsequent successful completion of PATHFINDER, Acurx plans to request... More